Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Santhera, Biovail Sign Drug Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Santhera, Biovail Sign Drug Pact

Santhera Pharmaceuticals and Biovail Corp. have signed a license agreement for Santhera's JP-1730/fipamezole, granting Biovail U.S. and Canadian rights to develop and commercialize the drug for the treatment of dyskinesia in Parkinson's Disease.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Santhera Pharmaceuticals and Biovail Corp. have signed a license agreement for Santhera’s JP-1730/fipamezole, granting Biovail U.S. and Canadian rights to develop and commercialize the drug for the treatment of dyskinesia in Parkinson’s Disease. In a recent Phase IIb study, JP-1730/ fipamezole showed the potential to reduce levodopa-induced dyskinesia.

“Biovail is an emerging key player in the area of neurodegenerative disorders. With its commitment to this therapeutic area and the strong track record it has developed in a short period of time, I am confident that JP-1730/fipamezole will become a key product for the improved management of Parkinson’s disease,” said Klaus Schollmeier, chief executive officer of Santhera. “Importantly, today’s agreement is consistent with our strategy of partnering larger indications whilst retaining co-promotional rights for our commercial operations in the U.S.”

Bill Wells, Biovail’s chief executive officer said, “This agreement with Santhera is directly on strategy and another important step in our efforts to build a sustainable product-development pipeline in specialty central nervous system disorders.”

Santhera will receive an upfront payment of $8 million and a further payment of $4 million upon the successful closing of its acquisition of Oy Juvantia Pharma Ltd. Biovail will pay as much as $35 million in development and regulatory milestones and will make additional sales milestone payments of as much as $145 million. Santhera will also receive royalties on sales of the drug. For a second indication, Santhera is eligible to receive as much as $20 million in success-based milestones.

Biovail will be responsible for the remaining clinical development programs in the U.S. and Canada. Initiation of the first Phase III study is scheduled for 2011. Santhera will retain co-promotion rights in the U.S.

Sign up today for Contracting & Outsourcing 2009!
contractpharma.com/2009conference

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters